-
-
- Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N, Ferrante M, Van Assche G et al. Gastroenterology. 2015 Jun;148(7):1320-9.e3
Estudio Taxit de monitorización de Infliximab en enfermedad inflamatoria intestinal.
- Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.
Papamichael K, Gils A, Rutgeerts P et al. Inflamm Bowel Dis. 2015 Jan;21(1):182-97.
Importancia de la monitorizacion de la dosis de carga en enfermedad inflamatoria intestinal.
- Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X, Rinaudo M, Del Tedesco E et al. Am J Gastroenterol. 2014 Aug;109(8):1250-6.
Algoritmo de monitorización de adalimumab en enfermedad inflamatoria intestinal.
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
A Jamnitski, CL Krieckaert, MT Nurmohamed et al. Ann Rheum Dis. 2012 Jan;71(1):88-91.
- Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clin Pharmacokinet. 2010 Aug;49(8):493-507.
Conceptos básicos sobre farmacocinética de Anticuerpos Monoclonales.
Para acceder al artículo pinchar aquí.
